CLAIMS

1. A method for evaluating an effect of an agent to be tested on skin, using a transgenic mouse to which an interleukin-18 gene under control of a keratinocyte promoter is introduced,

wherein the following (A) and/or (B) are used as an evaluation indicator.

- (A) spontaneous dermatitis
- (B) dermal inflammation at a time of the first administration of a phlogogenous material

10

5

- 2. The evaluation method according to claim 1, wherein the spontaneous dermatitis reaches its peak on the 8th to 12th day after birth.
- 3. The evaluation method according to claim 1, wherein the object of the
 evaluation is to screen an agent for preventing / treating autoimmune dermatitis.
 - 4. The evaluation method according to claim 2, wherein the object of the evaluation is to screen an agent for preventing / treating autoimmune dermatitis.
- 20 5. A method for evaluating an effect of an agent to be tested on alopecia, using a transgenic mouse to which an interleukin-18 gene under control of a keratinocyte promoter is introduced.
- 6. The evaluation method according to claim 5, wherein the object of the evaluation is to screen an agent for preventing or treating alopecia.
 - 7. An agent for preventing or treating dermatitis and/or alopecia, comprising a

substance that suppresses a cell having an NK1.1 antigen.

- 8. The agent for preventing or treating dermatitis and/or alopecia according to claim 7, wherein the substance that suppresses a cell having an NK1.1 antigen is an antibody against a cell having an NK1.1 antigen.
- 9. The agent for preventing or treating dermatitis and/or alopecia according to claim 8, wherein the antibody against a cell having an NK1.1 antigen is an antibody identifying an asialo GM1 antigen or antibody identifying an NK1.1 antigen.

10

5

- 10. A transgenic mouse used to evaluate an effect of an agent to be tested on alopecia, to which an interleukin-18 gene under control of a keratinocyte promoter is introduced.
- 15 11. The transgenic mouse according to claim 10, wherein the object of the evaluation is to screen an agent for preventing or treating alopecia.